Repare Therapeutics Under Its Worldwide License And Collaboration Agreement With Roche For Camonsertib, Has Earned A $40M Milestone Payment Upon Dosing Of The First Patient With In Roche's TAPISTRY Phase 2 Trial
Author: Benzinga Newsdesk | January 25, 2024 08:05am